Table 1. Comparison of clinical characteristics between the 2 groups.
| Variable | Category | EBV infected group (n=101) | EBV non-infected group (n=61) | χ2/t/P value |
|---|---|---|---|---|
| Gender | Male | 51 (50.50) | 26 (42.62) | 0.945/0.331 |
| Female | 50 (49.50) | 35 (57.38) | ||
| Age (years) | <1 | 4 (3.96) | 2 (3.28) | 0.161/0.923 |
| 1–10 | 32 (31.68) | 21 (34.43) | ||
| >10 | 65 (64.36) | 38 (62.30) | ||
| First symptoms | Fever | 27 (26.73) | 19 (31.15) | 34.650/<0.001 |
| Anemia | 14 (13.86) | 19 (31.15) | ||
| Subcutaneous hemorrhage | 6 (5.94) | 14 (22.95) | ||
| Hepatosplenic lymph node enlargement | 54 (53.47) | 6 (9.84) | ||
| Karyotype | Normal | 36 (35.64) | 42 (68.85) | 16.800/<0.001 |
| Abnormal | 65 (64.36) | 19 (31.15) | ||
| Immunotyping | T-cell type | 13 (12.87) | 55 (90.16) | 93.284/<0.001 |
| B-cell type | 88 (87.13) | 6 (9.84) | ||
| Fusion of genes | Negative | 78 (77.23) | 42 (68.85) | 1.389/0.239 |
| Positive | 23 (22.77) | 19 (31.15) | ||
| Clinical risk level | Low risk | 18 (17.82) | 26 (42.62) | 11.960/0.003 |
| Medium risk | 30 (29.70) | 14 (22.95) | ||
| High risk | 53 (52.48) | 21 (34.43) | ||
| Secondary infections during chemotherapy | Yes | 62 (61.39) | 26 (42.62) | 5.396/0.020 |
| No | 39 (38.61) | 35 (57.38) | ||
| Blood count indicators | WBC (×109/L) | 121.76±12.86 | 122.86±12.64 | 0.531/0.696 |
| Hb (g/L) | 117.86±11.98 | 116.99±11.86 | 0.450/0.654 | |
| PLT (×109/L) | 134.76±13.29 | 135.23±13.76 | 0.215/0.830 | |
| Lymphocyte subsets | CD3+ (%) | 42.13±4.25 | 60.22±6.86 | 20.740/<0.001 |
| CD4+ (%) | 31.87±3.54 | 40.97±5.52 | 12.790/<0.001 | |
| CD8+ (%) | 36.76±4.38 | 30.22±2.87 | 10.390/<0.001 | |
| CD4+/CD8+ | 0.80±0.11 | 0.97±0.13 | 8.892/<0.001 |
EBV, Epstein-Barr virus; WBC, white blood cell count; Hb, hemoglobin; PLT, platelet count; Data means n (%) or mean ± SD.